In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (ABT -0.03%), Johnson & Johnson (JNJ -1.15%), Sanofi (SNY 5.90%), Pfizer (PFE -3.85%), and Merck (MRK 2.93%), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.
Who's buying Bausch & Lomb?
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.